Compare POLA & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POLA | GTBP |
|---|---|---|
| Founded | 1979 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 8.8M |
| IPO Year | 2016 | 2016 |
| Metric | POLA | GTBP |
|---|---|---|
| Price | $2.02 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 165.8K | ★ 2.1M |
| Earning Date | 04-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,801,141.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $1.31 | $0.26 |
| 52 Week High | $5.70 | $3.73 |
| Indicator | POLA | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 59.30 | 57.51 |
| Support Level | $1.45 | $0.39 |
| Resistance Level | $2.20 | $0.79 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 76.49 | 83.08 |
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.